Bristol-Myers Squibb Sued for $450 Million Over Drug Acquisition
Bristol-Myers Squibb Co. plotted to rip off investors in a 2016 acquisition through legal gamesmanship aimed at evading a $450 million payment, according to a lawsuit unsealed Tuesday.
Bristol Myers Squibb Announces Dividend Increase
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company.
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slid 1.00% to $58.12 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.30% to 6,034.91 and Dow Jones Industrial Average DJIA falling 0.35% to 44,247.83.
Bristol Myers A Top Socially Responsible Dividend Stock With 4% Yield
The annualized dividend paid by Bristol Myers Squibb Co. is $2.4/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 10/04/2024
Bristol-Myers Squibb: Balancing Stability and Competition with Cautious Optimism
Analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
The stock's fall snapped a two-day winning streak.
Is Bristol Myers Squibb (BMY) a Great Value Stock Right Now?
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies,
Justice on the Move: The Impact of 'Bristol-Myers Squibb' on FLSA Forum-Shopping
Savvy plaintiffs-side attorneys are leveraging this split to avoid bringing their FLSA collective action where the employer ...
Modern Healthcare5h
These pharma lawsuits could transform 340B
Johnson & Johnson and other pharma companies aim to change how the 340B Drug Pricing Program functions. Courts must rule if ...
Health Rounds: New combination treatments promising for blood cancers
Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, researchers reported at the ...
Bristol Myers raises quarterly dividend 3.3% to 62c per share
Squibb announced that its Board of Directors has declared a quarterly dividend of 62c per share on the 10c par value common ...
FierceBiotech4h
Keros' stock tanks after halting 2 arms of hypertension trial over fluid buildups around heart
Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline ...
BioSpace3d
FDA Action Alert: Ionis, Lexicon, Bristol Myers Squibb and More
Ionis Pharmaceuticals is advancing the investigational RNA-targeted therapy olezarsen for the treatment of familial ...